Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose

References

• Weaver CH, Hazelton B Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of PB progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86:3961–3969.
   PubMed Web of Science ®Google Scholar
• Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995;13:2547–2555.
   PubMed Web of Science ®Google Scholar
• Pérez-Simón JA, Caballero MD, Corral M, et al. Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. Transfusion. 1998;38:385–391.
   PubMed Web of Science ®Google Scholar
• Bai L, Xia W, Wong K, et al. Factors predicting hematopoietic recovery in patients undergoing autologous transplantation: 11-year experience from a single center. Ann Hematol. 2014;93:1655–1664.
   PubMed Web of Science ®Google Scholar
• Bender JG, To LB, Williams S, et al. Defining a therapeutic dose of peripheral blood stem cells. J Hematother. 1992;1:329–341.
   PubMedGoogle Scholar
• Lefrère F, Delarue R, Somme D, et al. High-dose CD34+ cells are not clinically relevant in reducing cytopenia and blood component consumption following myeloablative therapy and peripheral blood progenitor cell transplantation as compared with standard dose. Transfusion. 2002;42:443–450.
   PubMed Web of Science ®Google Scholar
• Blystad AK, Delabie J, Kvaløy S, et al. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol. 2004;125:605–612.
   PubMed Web of Science ®Google Scholar
• Bolwell BJ, Pohlman B, Rybicki L, et al. Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant. 2007;40:437–441.
   PubMed Web of Science ®Google Scholar
• Malik S, Bolwell B, Rybicki L, et al. Apheresis days required for harvesting CD34+ cells predicts hematopoietic recovery and survival following autologous transplantation. Bone Marrow Transplant. 2011;46:1519–1525.
   PubMed Web of Science ®Google Scholar
• Stiff PJ, Micallef I, Nademanee AP, et al. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma . Biol Blood Marrow Transplant. 2011;17:1146–1153.
   PubMed Web of Science ®Google Scholar
• Lanza F, Campioni DC, Hellmann A, et al. Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation. Biol Blood Marrow Transplant. 2013;19:1670–1676.
   PubMed Web of Science ®Google Scholar
• Ketterer N, Salles G, Raba M, et al. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood. 1998;91:3148–3155.
   PubMed Web of Science ®Google Scholar
• Gorin NC, Labopin M, Reiffers J, et al. Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission. Blood. 2010;116:3157–3162.
   PubMed Web of Science ®Google Scholar
• Sharp JG, Kessinger A, Mann S, et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin’s lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol. 1996;14:214–219.
   PubMed Web of Science ®Google Scholar
• Vose JM, Sharp G, Chan WC, et al. Autologous transplantation for aggressive non-Hodgkin’s lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol. 2002;20:2344–2352.
   PubMed Web of Science ®Google Scholar
• Haas R, Moos M, Karcher A, et al. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 1994;12:1685–1692.
   PubMed Web of Science ®Google Scholar
• van der Wall E, Richel DJ, Holtkamp MJ, et al. Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size. Ann Oncol. 1994;5:795–802.
   PubMed Web of Science ®Google Scholar
• Yoon DH, Sohn BS, Jang G, et al. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin’s lymphoma. Transfusion. 2009;49:1890–1900.
   PubMed Web of Science ®Google Scholar
• Sutherland DR, Anderson L, Keeney M, et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother. 1996;5:213–226.
   PubMedGoogle Scholar
• Gordan LN, Sugrue MW, Lynch JW, et al. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin’s and non-Hodgkin’s Lymphoma. Bone Marrow Transplant. 2003;31:1009–1013.
   PubMed Web of Science ®Google Scholar
• Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918–3927.
   PubMed Web of Science ®Google Scholar
• Oliansky DM, Gordon LI, King J, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant. 2010;16:443–468.
   PubMed Web of Science ®Google Scholar
• Oliansky DM, Czuczman M, Fisher RI, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant. 2011;17:20–47.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Litzow MR, Inwards DJ, et al. Infused PB autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2004;33:291–298.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood. 2001;98:579–585.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Ingle JN, Litzow MR, et al. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant. 2001;28:865–871.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Litzow MR, Tefferi A, et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia. 2002;16:1311–1318.
   PubMed Web of Science ®Google Scholar
• Jimenez-Zepeda VH, Reece DE, Trudel S, et al. Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant. Leuk Lymphoma. 2015;56:2668–2673.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Litzow MR, Markovic SN. Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo Clin Proc. 2001;76:407–412.
   PubMed Web of Science ®Google Scholar
• Schulman KA, Birch R, Zhen B, et al. Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol. 1999;17:1227
   PubMed Web of Science ®Google Scholar
• Olivieri A, Offidani M, Montanari M, et al. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Haematologica. 1998;83:329–337.
   PubMed Web of Science ®Google Scholar